Status:
UNKNOWN
[68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer
Lead Sponsor:
Huashan Hospital
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The aim of this study was to establish and optimize the imaging method of \[68Ga\]Ga-NOTA-RW102, as well as its physiological and pathological distribution characteristics, on the basis of which the d...
Eligibility Criteria
Inclusion
- Patients with PD-L1-positive non-small cell lung cancer
- Age between 18 and 65 years old, gender is not limited.
- Patients with CT findings that can be occupied on the lung with a diameter greater than 1cm or more who have not undergone surgery.
- Lung cancer patients with a clinical diagnosis of positive PD-L1 expression;
- Written informed consent must be signed by the subject or his/her legal guardian or caregiver.
- Willingness and ability to cooperate with all programs of this study.
Exclusion
- Subjects meeting any of the following criteria will be excluded from the study:
- Severe hepatic and renal insufficiency;
- Targeted therapy prior to radiotherapy or PET/CT scan. PD-L1 expression in existing lesions was assessed by immunohistochemistry using antibody clone 22C3. Renal function: serum creatinine less than or equal to the upper limit of the normal range;
- Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range.
- History of serious surgery in the last month.
- Those who have participated in other clinical trials during the same period.
Key Trial Info
Start Date :
March 12 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 14 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06165874
Start Date
March 12 2023
End Date
January 14 2024
Last Update
December 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital
Shanghai, China, 200040